Febarbamate

DB13303

small molecule experimental

Deskripsi

Struktur Molekul 2D

Berat 405.451
Wujud -

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

668 Data
Buprenorphine Febarbamate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Febarbamate.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Febarbamate.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Febarbamate.
Hydrocodone Febarbamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Febarbamate.
Magnesium sulfate The therapeutic efficacy of Febarbamate can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Febarbamate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Febarbamate may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Febarbamate.
Mirtazapine Febarbamate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Febarbamate.
Orphenadrine Febarbamate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Febarbamate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Febarbamate.
Pramipexole Febarbamate may increase the sedative activities of Pramipexole.
Ropinirole Febarbamate may increase the sedative activities of Ropinirole.
Rotigotine Febarbamate may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Febarbamate.
Sodium oxybate Febarbamate may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Febarbamate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Febarbamate.
Thalidomide Febarbamate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Febarbamate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Febarbamate.
Ethanol Febarbamate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Febarbamate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Febarbamate.
Fluvoxamine The risk or severity of adverse effects can be increased when Febarbamate is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Febarbamate is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Febarbamate is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Febarbamate is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Febarbamate is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Febarbamate is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Febarbamate is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Febarbamate is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Febarbamate is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Febarbamate is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Febarbamate is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Febarbamate is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Febarbamate is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Febarbamate is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Febarbamate is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Febarbamate is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Febarbamate is combined with Alaproclate.
Amitriptyline The risk or severity of CNS depression can be increased when Amitriptyline is combined with Febarbamate.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Febarbamate.
Imipramine The risk or severity of CNS depression can be increased when Imipramine is combined with Febarbamate.
Nortriptyline The risk or severity of CNS depression can be increased when Nortriptyline is combined with Febarbamate.
Amoxapine The risk or severity of CNS depression can be increased when Amoxapine is combined with Febarbamate.
Propiomazine The risk or severity of CNS depression can be increased when Propiomazine is combined with Febarbamate.
Maprotiline The risk or severity of CNS depression can be increased when Maprotiline is combined with Febarbamate.
Doxepin The risk or severity of CNS depression can be increased when Doxepin is combined with Febarbamate.
Desipramine The risk or severity of CNS depression can be increased when Desipramine is combined with Febarbamate.
Pizotifen The risk or severity of CNS depression can be increased when Pizotifen is combined with Febarbamate.
Dosulepin The risk or severity of CNS depression can be increased when Dosulepin is combined with Febarbamate.
Zopiclone The risk or severity of adverse effects can be increased when Febarbamate is combined with Zopiclone.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Febarbamate.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Febarbamate.
Tryptophan The risk or severity of CNS depression can be increased when Tryptophan is combined with Febarbamate.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Febarbamate.
Lorazepam The risk or severity of CNS depression can be increased when Lorazepam is combined with Febarbamate.
Ethchlorvynol The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Febarbamate.
Succinylcholine The risk or severity of CNS depression can be increased when Succinylcholine is combined with Febarbamate.
Reserpine The risk or severity of CNS depression can be increased when Reserpine is combined with Febarbamate.
Eletriptan The risk or severity of CNS depression can be increased when Eletriptan is combined with Febarbamate.
Enflurane The risk or severity of CNS depression can be increased when Enflurane is combined with Febarbamate.
Temazepam The risk or severity of CNS depression can be increased when Temazepam is combined with Febarbamate.
Reboxetine The risk or severity of CNS depression can be increased when Reboxetine is combined with Febarbamate.
Butabarbital The risk or severity of CNS depression can be increased when Butabarbital is combined with Febarbamate.
Butalbital The risk or severity of CNS depression can be increased when Butalbital is combined with Febarbamate.
Methysergide The risk or severity of CNS depression can be increased when Methysergide is combined with Febarbamate.
Cabergoline The risk or severity of CNS depression can be increased when Cabergoline is combined with Febarbamate.
Phenytoin The risk or severity of CNS depression can be increased when Phenytoin is combined with Febarbamate.
Topiramate The risk or severity of CNS depression can be increased when Topiramate is combined with Febarbamate.
Clemastine The risk or severity of CNS depression can be increased when Clemastine is combined with Febarbamate.
Venlafaxine The risk or severity of CNS depression can be increased when Venlafaxine is combined with Febarbamate.
Etomidate The risk or severity of CNS depression can be increased when Etomidate is combined with Febarbamate.
Morphine The risk or severity of CNS depression can be increased when Morphine is combined with Febarbamate.
Talbutal The risk or severity of CNS depression can be increased when Talbutal is combined with Febarbamate.
Pentobarbital The risk or severity of CNS depression can be increased when Pentobarbital is combined with Febarbamate.
Valproic acid The risk or severity of CNS depression can be increased when Valproic acid is combined with Febarbamate.
Zolmitriptan The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Febarbamate.
Codeine The risk or severity of CNS depression can be increased when Codeine is combined with Febarbamate.
Dihydroergotamine The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Febarbamate.
Tolcapone The risk or severity of CNS depression can be increased when Tolcapone is combined with Febarbamate.
Hydromorphone The risk or severity of CNS depression can be increased when Hydromorphone is combined with Febarbamate.
Olanzapine The risk or severity of CNS depression can be increased when Olanzapine is combined with Febarbamate.
Cetirizine The risk or severity of CNS depression can be increased when Cetirizine is combined with Febarbamate.
Protriptyline The risk or severity of CNS depression can be increased when Protriptyline is combined with Febarbamate.
Trimethadione The risk or severity of CNS depression can be increased when Trimethadione is combined with Febarbamate.
Clobazam The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Febarbamate.
Chlorzoxazone The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Febarbamate.
Clozapine The risk or severity of CNS depression can be increased when Clozapine is combined with Febarbamate.
Meprobamate The risk or severity of CNS depression can be increased when Meprobamate is combined with Febarbamate.
Thiethylperazine The risk or severity of CNS depression can be increased when Thiethylperazine is combined with Febarbamate.
Palonosetron The risk or severity of CNS depression can be increased when Palonosetron is combined with Febarbamate.
Sulpiride The risk or severity of CNS depression can be increased when Sulpiride is combined with Febarbamate.
Alprazolam The risk or severity of CNS depression can be increased when Alprazolam is combined with Febarbamate.
Dexbrompheniramine The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with Febarbamate.

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 4
International Brands
  • G-Tril
  • Getril
  • Solium
  • Tymium

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul